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Abstract: The widespread emergence of antibiotic-resistant bacteria has highlighted the urgent
need of alternative therapeutic approaches for human and animal health. Targeting virulence
factors that are controlled by bacterial quorum sensing (QS), seems a promising approach.
The aims of this study were to generate novel nanoparticles (NPs) composed of chitosan (CS),
sulfo-butyl-ether-β-cyclodextrin (Captisol®) and/or pentasodium tripolyphosphate using ionotropic
gelation technique, and to evaluate their potential capacity to arrest QS in bacteria. The resulting
NPs were in the size range of 250–400 nm with CS70/5 and 330–600 nm with CS70/20, had low
polydispersity index (<0.25) and highly positive zeta potential ranging from ζ ~+31 to +40 mV.
Quercetin, a hydrophobic model flavonoid, could be incorporated proportionally with increasing
amounts of Captisol® in the NPs formualtion, without altering significantly its physicochemical
properties. Elemental analysis and FTIR studies revealed that Captisol® and quercetin were effectively
integrated into the NPs. These NPs were stable in M9 bacterial medium for 7 h at 37 ◦C. Further,
NPs containing Captisol® seem to prolong the release of associated drug. Bioassays against an E. coli
Top 10 QS biosensor revealed that CS70/5 NPs could inhibit QS up to 61.12%, while CS70/20 NPs
exhibited high antibacterial effects up to 88.32%. These results suggested that the interaction between
NPs and the bacterial membrane could enhance either anti-QS or anti-bacterial activities.
Keywords: quercetin; chitosan; Captisol®; cyclodextrin; nanoparticles; quorum sensing inhibitors;
E. coli Top 10
1. Introduction
The current poor efficacy of antibiotics to treat bacterial disease, due to the increasing widespread
emergence of resistance, highlights the urgent need for alternative therapeutic strategies. Rather than
focusing on targeting bacteria either by bactericidal or bacteriostatic agents, targeting their virulence
and associated factors, seems a more promising alternative approach. Such virulence factors are
required for infection (e.g., toxin function and delivery, regulation of virulence expression and
bacterial adhesion); they seem to be preserving the endogenous host microbiome and impose less
selective pressure on pathogenic bacteria and in theory, decrease resistance [1]. Many bacteria use a
cell-cell communication process termed quorum sensing (QS) to communicate, coordinately regulate
their gene expression and synchronise their collective social behaviours, such as biofilm formation,
bioluminescence and secretion of virulence factors [2,3]. QS involves the production, detection of,
and response to extracellular signalling molecules known as autoinducers [4]. QS is not essential for
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the growth of bacteria though. Thus, its exquisite disruption (known as “quorum quenching”, QQ)
offers the possibility to disarm the virulence capacity, rather than killing the bacteria, thus leading to
weaken the selective pressure imposed on the pathogens and postpone the evolution of resistance to
QQ drugs [5]. Accordingly, this approach appears as a promising strategy for anti-virulence therapy [4].
Nanobiotechnology has opened new possibilities to develop innovative nanomaterial systems with
antibacterial and with QQ capacity [6,7]. Ideal QQ therapeutic compounds need not only to exhibit
a low toxicity profile, but also suitable pharmacokinetic characteristics for clinical applications.
Many potential new molecules reveal promising high QQ efficacy, but they are not considered
further due to their low intestinal absorption [8]. As reported by the Biopharmaceutics Classification
System, drugs can be classified based on their solubility and permeability. According with this
classification, four classes of drugs have been proposed: Class 1 (high solubility, high permeability),
Class 2 (low solubility, high permeability), Class 3 (high solubility, low permeability) and Class 4
(low solubility, low permeability) [9]. Except Class 1, compounds in the three remaining groups lack
either solubility or permeability, both very important attributes that dictate the bioavailability of drugs
through biological membranes. The continuous discovery of many new drug candidates which fail
because of low oral bioavailability [10], highlights the need for designing delivery systems capable to
overcome these problems [8].
Among the drug delivery strategies intended to increase the bioavailability of drugs,
the use of polymeric nanocarriers has received significant traction. Chitosan refers to a family
of linear, semi-crystalline polysaccharide composed of randomly distributed β (1→4)-linked
N-acetyl D-glucosamine (acetylated unit) and D-glucosamine (deacetylated unit) and constitute
a unique class of biopolymers [11]. Commercially available chitosans produced by chemical
methods vary mostly on their degree of acetylation (DA) and molar mass. In addition, using
enzymatic and biorefinery approaches, Moerschbacher from our University, has pursued the objective
of obtaining a new generation of chitosans with specific non-random PAs [12]. To be termed
“chitosan”, the deacetylated chitin should contain at least 60% of D-glucosamine residues [13], which
corresponds to a degree of acetylation of 40% (i.e., degree of deacetylation 60%). Chitosan’s DA
can vary widely in the range 0 to over ~60%, while the molar mass commonly ranges from ~3
to ~400 kg/mol, depending on the source and preparation method. Chitosan exhibits remarkable
unique bioactive properties which include biocompatibility, biodegradability [14,15], bioadhesion,
absence of allergenicity and toxicity, anti-hypercholesterolemic [16,17], antibacterial activity [18], along
with antifungal [19], mucoadhesive [20,21], analgesic [19] and haemostatic properties [22]. Due to
these features, chitosan has been presented as an outstanding candidate for biomedical applications,
food industrial applications, cosmetics, and pharmaceutics [16]. The broad spectrum antimicrobial
activity of chitosan has been widely applied in food preservation since edible chitosan coatings
help to preserve vegetables and meat and fish products [23–25] result in reducing the amount of
synthetic preservatives. Chitosan has shown effective antibacterial activity in both Gram-positive
and Gram-negative bacteria. Greatest growth reduction in gram positive Bacillus cereus treated with
different Mw chitosan oligomers and polymers ranging from ~3 to ~21 kg/mol was observed with
chitosan of Mw ~11 kg/mol and DA ~41% [26]. The same effect has been recorded with gram negative
E. coli treated with chitosans of different Mw varying from 5 to 91.6 kg/mol where the lower Mw,
the better antibacterial activity will be achieved [27]. In another study, the influence of chitosan’s DA
on antibacterial activity was conducted, which showed that only chitosans with low DA (4% and
10%) inhibit the growth by 30% after 16 h of fermentation [28]. Despite the existing experimental
evidence, the precise mechanisms of the antimicrobial effects of chitosan oligomers and polymers
remain elusive to date. Two main mechanisms have been proposed to account for chitosan antibacterial
and antifungal activities. The first proposal argues that positively charged chitosan and its derivatives
can electrostatically interact with negatively charged groups (exp. phospholipid and proteins) at the
surface of the cell membrane, and therefore, alters its permeability leading to cellular leakage. Under
this proposal, it has also been suggested that there are hydrophobic interations between chitosan and
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phopholipid membrane of Gram-negative bacteria [29]. This process would prevent essential materials
to enter the cells or/and lead to the leakage of fundamental solutes out of the cell [30]. The second
mechanism involves the penetration of water-soluble chitosan into the cytosol and binding to cell
DNA (still via protonated amino groups), which would lead to the inhibition of the microbial RNA
synthesis and DNA transcription [31]. Chitosan antimicrobial properties might in fact result from a
combination of both type of mechanisms [32,33].
In our laboratory, we have been researching on alternative approaches to the indiscriminate use
of antibiotics against pathogenic bacteria. In this respect, the development of new chitosan-based
nanomaterials aimed to interfere with bacterial quorum sensing, is of particular interest. Quorum
sensing enables bacteria respond to differences in cell-density by means of producing and detecting
the accumulation of signaling molecules [34]. To this end, we have used an E. coli Top 10
biosensor that carries a synthetic genetic device based on the luxR/luxI QS genetic circuitry of
Vibrio fischeri. This biosensor was originally proposed to detect N-(3-oxohexanoyl)-L-homoserine
lactone (3OC6HSL) [35]. At an adequate concentration, two molecules of 3OC6HSL, bind to two
molecules of the receptor LuxR, and activate the expression of green fluorescent protein (output),
which is under the lux pR promoter from Vibrio fischeri. This biosensor achieves a sensitivity towards
3OC6HSL of <1 nM [36]. We have successfully developed nanocarriers made of the polysaccharide
chitosan (CS) which possess inherent mucoadhesive properties to increase the systemic absorption
of drugs [37]. It has been documented that the interaction of CS nanoparticles with the mucus
layer facilitates the transport of the associated drug to the underlying epithelium. On the other
hand, cyclodextrins (CD), well-known cyclic oligosaccharides, have a hydrophobic central cavity
and a hydrophilic outer surface, and hence, they can form inclusion complexes with hydrophobic
compounds. The inclusion complexes are known to contribute to enhance the solubility and stability of
the drugs [38–41]. Due to a higher water solubility and a better biocompatibility profile, cyclodextrin
derivatives such as sulfobutyl-ether-β-cyclodextrin (SBEβCD), known also under the commercial
brand name Captisol®, carboxymethyl β-cyclodextrin (CM-β-CD) and hydroxypropyl β-cyclodextrin
(HP-β-CD) derivatives, have been used in drug formulation, particularly, for Class 2 and 4 drugs (low
solubility and low permeability).
Emerging studies suggest that flavonoid compounds have many significant effects in natural
anti-virulence applications [42–45]. However, many of these compounds suffer from poor water
solubility, low chemical stability and little bioavailability [46]. To overcome some of these caveats,
it has been proposed that encapsulating in biopolymer-based materials, the activity of anti-virulent
agents or anti-microbial could be improved [47,48]. This might be attributed to the increase in
their bioavailability, as well as the prolongation in their release with lower doses to overcome the
resistances offered by physiological barriers as compared with free agents [49,50]. In this study, we have
chosen quercetin as a model flavonoid payload and evaluated the feasibility of its incorporation and
delivery using chitosan/SBEβCD-based nanoparticles. Quercetin is a common natural polyphenolic
flavonoid compound, found ubiquitously in plants, including food products like onions, many fruits,
or in herbs [51,52]. Many reported studies agree that quercetin has a wide range of biological
activities including anti-virulence/anti-biofilm formation agent [53], anticancer [54], antioxidant [55]
and to reduce the blood pressure in hypertensive subjects [56,57]. However, these activities are
somewhat compromised due to the low aqueous solubility and gastrointestinal instability [58].
Quercetin is normally present as a glycoside that is absorbed in the small intestine and converted
into glucuronide and sulfate conjugates that render the molecule inactive to allow for its excretion
through urine [59]. Most of quercetin occurring in plants as hydrophilic glycosides have limited
direct absorption [60]. According to researches on human volunteers, no quercetin was detected in
the plasma or urine after oral administration in a dose of 4 g [61]. Furthermore, quercetin has been
disappeared immediately from plasma of rodents administered intravenously. This suggested that
quercetin could be metabolized speedily and the accumulation in tissues and biological fluids is very
negligible [62]. More recent in vivo studies, suggest that quercetin metabolites can also function as
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carriers that transport quercetin into different tissues, such as vascular, where β-glucuronidase will
deconjugate it into the aglycone form which has the most biological effect [57]. It may be that the
entrapment of quercetin in chitosan-cyclodextrin nanoparticles might help to improve the solubility,
potentiate the biological effects and improve the bioavailability of quercetin in a controlled manner.
Chitosan/cyclodextrin nanoparticles have been reported as potential carriers for the oral delivery of
small peptides [63] as well as for the gene delivery to the airway epithelium [64]. In the present work,
we aimed to design a novel anti-QS formulation that combine the virtues of chitosan and Captisol®
nanoparticles in terms of association for quercetin, modulating the release profile and enhancing the
anti-QS efficacy using a E. coli Top 10 AHL-regulated biosensor.
2. Results
2.1. Preparation of Unloaded Nanoparticles
Nanoparticles composed of chitosan, and either SBEβCD or mixtures of SBEβCD/TPP,
were obtained via the ionotropic gelation technique [65]. This method is based on the ionic interaction
between the positively charged CS and the negatively charged TPP and/or SBEβCD, and the
ability of CS to form inter- and intra-molecular linkages with poly-anions thus resulting in the
formation of colloidal particles. By contrast with macroscopic gelation, this process occurs in
dilute conditions. The process is extremely mild as it only involves the mixture of two aqueous
phases at room temperature. Previous studies have reported the use of the neutral hydroxypropyl
β-cyclodextrin derivative in association with CS to form nanoparticles [66,67]. In this study we
decided to choose a negatively charged cyclodextrin derivative-SBEβCD, which allegedly could
be incorporated more effectively into nanoparticles due to stronger ionic interactions with the
positively charged CS. Nanoparticles could be prepared either in the presence or absence of TPP
by mixing CS with different amounts of SBEβCD (Tables 1 and 2). The resulting NPs prepared
with CS70/5 and CS70/20 were in the size range of 250–400 and 330–600 nm, PDI 0.03–0.19 and
0.13–0.25, respectively, and invariably high positive zeta potential ranging from +31 to +40 mV.
Generally, if the contents of initial anionic charged species (SBEβCD and/or TPP) was too low
(e.g., CS/CD/TPP mass ratio 4/1/0 and 4/2/0 in Tables S1 and S2), NPs either did not form
or their yields were too low for characterization. On the other hand, too much of initial anionic
charged species, resulted in either aggregation or the NPs could not be re-suspended after isolation
(Figures 1 and 2). We reasoned that when a fixed amount of CS was used, the amount of cyclodextrin
that is adequate for NPs formation varied with the proportion of Captisol® which carries more than
six sulfate charges per mol (SBEβCD, D.S. ≈ 6.4), as well as the presence of TPP cross-linker, which is
supposed to compete with SBEβCD for the positively charged amino group of CS. If the net charge
ratio (+/−) ranges from 0.75 to 1.25 (near the isoelectric point), precipitation occurred immediately
(e.g., CS/CD/TPP mass ratio 4/1.5/1, 4/2/0.75, 4/3/0.5 and 4/4/0.25 in Tables S1 and S2). Around
this point, NPs of greater size were obtained (e.g., at CS70/20/CD/TPP mass ratio 4/4/0 charge
ratio ≈ 1.5). Our results are consistent with previous works [66], that report when the SBEβCD/TPP
ratio decreased, the size, zeta potential and production yield of NPs increased (cf. mass ratio 4/1/0.5
vs. 4/2/0.25 in Table 1; and mass ratio 4/1/0.75 vs. 4/2/0.5 in Table 2). The lower zeta potential
with increasing SBEβCD amounts in these formulations could be explained by an increased masking
of free positively charged amino groups of CS. It also might be noted that TPP incorporated in the
formulation helps to increase the production yield.
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Table 1. Physicochemical properties of unloaded CS70/5/SBEβCD/TPP nanoparticles (mean ± S.D.,
n = 3).
Mass Ratio
CS/CD/TPP (w/w/w) Charge Ratio (+/−) Z-Average Size (d. nm) PDI ζ-Potential (mV)
Production
Yield (%)
4/0/0.75 2.50 413 ± 11 0.15–0.19 +36.9 ± 0.6 69.0 ± 3.2
4/0/0.5 3.75 256 ± 05 0.04–0.10 +36.8 ± 0.8 37.7 ± 1.5
4/1/0.5 2.18 323 ± 18 0.03–0.17 +38.0 ± 0.2 48.3 ± 1.3
4/2/0.25 1.93 259 ± 09 0.04–0.13 +36.3 ± 0.5 45.4 ± 2.0
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CS/CD/TPP (w/w/w) Charge Ratio (+/−) Z-Average Size (d. nm) PDI ζ-Potential (mV)
Production
Yield (%)
4/3/0 2.08 378 ± 14 0.16–0.22 +31.0 ± 0.9 40.5 ± 5.7
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2.2. Preparation and Characterization of Quercetin-Loaded Cyclodextrin-Containing CS Nanoparticles
NPs loaded with quercetin were prepared. To achieve a comprehensive picture of the encapsulation
process of this compound in the NPs, phase-solubility studies with increasing SBEβCD concentrations
were performed (Figure 3). As expected, quercetin showed a marked increase in their solubility as the
SBEβCD concentration increased. In fact, a 325-fold increase in quercetin solubility was achieved using
40 mM SBEβCD solutions [66]. Tables 3 and 4 show the size, PDI, zeta potential and production yield
of quercetin-loaded NPs of CS70/5 and CS70/20, respectively. In all formulations, positive zeta potential
values were detected, suggesting that CS is mainly located on the surface of the particles. The addition
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of quercetin did not change significantly the physicochemical properties of the NPs, except for the PDI
of the CS70/20- SBEβCD NP formulations that increased slightly.
Table 3. Physicochemical properties of CS70/5/SBEβCD/TPP quercetin-loaded nanoparticles
(mean ± S.D., n = 3).
Mass Ratio
CS/CD/TPP (w/w/w) Charge Ratio (+/−) Z-Average Size (d. nm) PDI ζ-Potential (mV)
Production
Yield (%)
4/0/0.75 2.50 444 ± 08 0.200–0.220 +35.4 ± 1.67 68.77 ± 3.18
4/0/0.5 3.75 316 ± 08 0.062–0.118 +35.5 ± 0.42 49.85 ± 4.92
4/1/0.5 2.18 319 ± 14 0.037–0.131 +37.2 ± 0.45 61.63 ± 5.11
4/2/0.25 1.93 270 ± 05 0.042–0.114 +35.5 ± 0.32 52.86 ± 2.19
Molecules 2017, 22, 1975 6 of 23 
 
 
Figure 3. Phase solubility of quercetin in the presence of increasing concentration of SBEβCD. 
Table 4. Physicochemical properties of CS70/20/SBEβCD/TPP quercetin-loaded nanoparticles (mean ± S.D., 
n = 3). 
Mass Ratio 
CS/CD/TPP (w/w/w) 
Charge Ratio (+/−) 
Z-Average Size 
(d. nm) 
PDI ζ Potential (mV) Production 
Yield (%) 
4/0/1 2.25 390 ± 24 0.21–0.28 +32.4 ± 1.91 64.24 ± 3.60 
4/0/0.75 3.00 485 ± 31 0.30–0.38 +29.3 ± 2.01 54.49 ± 7.88 
4/3/0 2.08 332 ± 07 0.17–0.26 +31.5 ± 1.29 45.98 ± 3.48 
4/4/0 1.56 572 ± 27 0.22–0.27 +32.8 ± 0.25 68.48 ± 5.21 
4/1/0.75 2.03 401 ± 13 0.21–0.24 +35.3 ± 0.92 74.48 ± 6.09 
4/2/0.5 1.85 397 ± 21 0.16–0.26 +39.0 ± 0.75 72.69 ± 3.75 
In previous studies, it has been shown that at least 99% of the maximum drug solubility was 
already reached in 24 h [66]. This result allowed to reduce drug/SBEβCD incubation time to 24 h for 
the solutions intended for loaded NP preparation. In the next step, we investigated how the 
solubilization of quercetin by its inclusion on the CD cavity could facilitate the association of the 
complexed flavonoid to CS NPs (Figure 4a,b). As the amount of Captisol® increased, the amount of 
flavonoid-complexed with Captisol®, and the final loading of NPs increased too. With CS70/5, when 
compared with the control formulation 4/0/0.75, the loading efficiency (LE) of 4/1/0.5 and 4/2/0.25 
increased 1.96- and 2.98-fold, respectively (Figure 4a). With CS70/20, when compared with the control 
formulation 4/0/1, the LE of 4/1/0.75 and 4/2/0.5 increased 2.87- and 4.5-fold, respectively (Figure 4b). 
Specifically, with NP formulations 4/3/0 and 4/4/0, the LE increase up to 7.33- and 8.1-fold, 
respectively, when compared with the control formulation, thus suggesting that the LE increased in 
proportion with the increase of the amount of Captisol®. As can observed from Tables S3 and S4, 
formulations without Captisol®, the LE achieved was very low. By contrast, when the amount of TPP 
decreased, the encapsulation efficiency (EE) and LE were elevated, thus effectively suggesting that 
TPP might compete with quercetin during the association with CS in these formulations (CS70/5 4/0/1 
vs. 4/0/0.75; CS70/20 4/0/0.75 vs. 4/0/0.5). 
Figure 3. Phase solubility of quercetin in the presence of increasing concentration of SBEβCD.
Table 4. Physicochemical properties of CS70/20/SBEβCD/TPP quercetin-loaded nanoparticles
(mean ± S.D., n = 3).
Mass Ratio
CS/CD/TPP (w/w/w) Charge Ratio (+/−) Z-Average Size (d. nm) PDI ζ Potential (mV)
Production
Yield (%)
4/0/1 2.25 390 ± 24 0.21–0. +32.4 ± 1.91 64.24 ± 3.60
4/0/0.75 3.00 485 ± 31 0.30–0.38 +29.3 ± 2.01 54.49 ± 7.88
4/3/0 2.08 332 ± 07 0.17–0.26 +31.5 ± 1.29 45.98 ± 3.48
4/4/0 1.56 572 ± 27 0.22–0.27 +32.8 ± 0.25 68.48 ± 5.21
4/1/0.75 2.03 401 ± 13 0.21–0.24 +35.3 ± 0.92 74.48 ± 6.09
4/2/0.5 1.85 397 ± 21 0.16–0.26 +39.0 ± 0.75 72.69 ± 3.75
In previous studies, it has been shown that at least 99% of the maximum drug solubility was
already reached in 24 h [66]. This result allowed to reduce drug/SBEβCD incubation time to 24 h
for the solutions intended for loaded NP preparation. In the next step, we investigated how the
solubilization of quercetin by its inclusion on the CD cavity could facilitate the association of the
complexed flavonoid to CS NPs (Figure 4a,b). As the amount of Captisol® increased, the amount
of flavonoid-complexed with Capt sol®, a d the fin l loading of NPs incr ased too. With CS70/5,
when compared with the control formulation 4/0/0.75, the loading efficiency (LE) of 4/1/0.5 and
4/2/0.25 increased 1.96- and 2.98-fold, respectively (Figure 4a). With CS70/20, when compared with the
control formulation 4/0/1, the LE of 4/1/0.75 and 4/2/0.5 increased 2.87- and 4.5-fold, respectively
(Figure 4b). Specifically, with NP formulations 4/3/0 and 4/4/0, the LE increase up to 7.33- and 8.1-fold,
respectively, when compared with the control formulation, thus suggesting that the LE increased in
proportion with the increase of the amount of Captisol®. As can observed from Tables S3 and S4,
formulations without Captisol®, the LE achieved was very low. By contrast, when the amount of TPP
decreased, the encapsulation efficiency (EE) and LE were elevated, thus effectively suggesting that
Molecules 2017, 22, 1975 7 of 23
TPP might compete with quercetin during the association with CS in these formulations (CS70/5 4/0/1
vs. 4/0/0.75; CS70/20 4/0/0.75 vs. 4/0/0.5).Molecules 2017, 22, 19 5 7 of 23 
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2.3. Elemental Analysis of Selected NPs
Many approaches have been proposed for the quantification of SBEβCD in nanoparticle carrier
systems. Most of them rely on colourimetric reactions of the cyclodextrin with an appropriate
reagent (e.g., fading of phenolphthalein reaction) [63,68]. These methods are useful, however, the
need for either lyophilized of the supernatant of NPs or using the enzymatic reaction at 40 ◦C for
60 min in 2% starch, have limited their application. In this study, elemental analysis was performed
to determine the composition of the different nanoparticle formulations (Figure 5). Using this
technique, the composition of the NPs could be determined by comparing the C–N mass ratios (or the
C–N–S mass ratios) of CS and SBEβCD with those of the NPs. CS/SBEβCD/TPP (CS70/5 4/0/0.75
and CS70/20 4/0/1) NPs were analyzed and taken as the references for SBEβCD-containing NP
formulations. Their compositions were 68.93% CS, 31.07% TPP and 72.73% CS, 27.27% TPP for CS70/5
and CS70/20 NPs, respectively. These values are close to the expected ones from theoretical ratios
at which the materials were incorporated. As expected, the anionic SBEβCD could be incorporated
into the NPs with considerable high efficiency: 41.03 and 34.5% (w/w) of the final composition
NPs corresponding to the respective SBEβCD incorporated (CS70/5 4/2/0.25 and CS70/20 4/2/0.5,
respectively). Particularly, SBEβCD was effectively entrapped into the CS70/20 4/3/0 NPs, representing
up to 52.7% of the total components of the nanoparticles.
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2.4. Stability Studies
As the final intended application of these nanoparticles is their use for anti-QS in gram negative
bacteria, we determined their stability in M9 medium (pH 6.8 and 37 ◦C). The results showed that
both loaded and unloaded nanoparticles did not suffer a significant change in their size following
incubation for 7 h (Figure 6a–d). The size varied within a small range 300–500 and 200–400 nm for
unloaded and quercetin-loaded NPs, respectively. However, upon contact with M9 medium some
formulations exhibited a size increase which could be attributed to a swelling effect. There was a
slight variation in PDI of these NPs during the first 3 h, after that the PDI tended to stabilize at ~0.5
and ~0.3 for unloaded (Figure 6a,c) and quercetin-loaded (Figure 6b,d) formulations, respectively.
Previous studies have also shown the possible role of cyclodexrtins in particle stabilization [66,67,69].
The colloidal stability is very important, since it maximizes the number of NPs covering the surface of
bacteria as well as maintaining the inherent surface effect to volume ratio of these NPs.
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2.5. In Vitro Release of Quercetin
As can be appreciated from Figure 7, in formulations without Captisol®, the encapsulated
quercetin was released up to 90% within 60 min. The fast release of quercetin from the nanometric
matrix could be explained because of its weak interaction with chitosan. This result was in accordance
with previous studies where almost all the payload was released from CS/TPP NPs in 15 min [66,70].
In contrast, nanoformulations containing Captisol® seem to prolong the release of the loaded-drug.
The different composition of these NPs regarding different amounts of TPP and Captisol® has a
negligible influence on the release profile of quercetin when around 40% of quercetin was released
after 6 h incubated in M9 medium at 37 ◦C. The slow release of quercetin in these formulations could
be understood as the expected consequence of the inclusion complexes formed by the hydrophobic
cavity of Captisol® and quercetin. The strong interaction between drug and Captisol® might have an
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impact in controlling the drug release. Previous studies have reported the ability of Captisol® to form
inclusion complexes with auto-inducers, especially with AHL with acyl tail from C4 to C8 [71–74],
hence we speculated that the drug release rate might be increased significantly when AHL is added
to the bacterial medium leading to the competition of AHL and quercetin to occupy the cavity of
Captisol®. The simultaneously burst release of loaded-drugs (vancomycin and hamamelitannin)
within 1 h and the uptake auto-inducers (either C6HSL or 3-oxo-C12HSL) was reported elsewhere [75].
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Figure 7. Quercetin in vitro release profile of selected loaded nanoparticles of CS70/5 (a) and CS70/20
(b) in M9 medium at 37 ◦C (mean ± S.D., n = 3) at varying mass ratios of CS/SBEβCD/TPP shown
in labels.
2.6. FTIR Analysis of Selected NPs
Fourier transform infrared spectroscopy (FTIR) analyses were performed on freeze-dried samples
of selected loaded NPs to identify the infrared absorption peaks of quercetin, chitosan, Captisol®,
unloaded, quercetin-loaded NPs and to investigate a possible reaction between quercetin and NPs
(Figure 8).
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The FTIR spectrum of free quercetin displayed bands and typical molecular peaks of its structure
such as: 1381 cm−1 (C–OH), 1610 cm−1 (C=C), 1262 cm−1 (C–O–C), 1662 cm−1 (C=O), and 3408 cm−1
(O–H stretch). CS70/20’s FTIR spectrum showed its characteristic bands with peaks at 1657 cm−1
and 1599 cm−1 attributed to NH-bending units of glucosamine. The absorption bands at 1033 cm−1
(C−O–C) and 1075 cm−1 (skeletal vibration involving the C–O stretching) are attributed to its regular
saccharide structure. In loaded NPs 4/2/0.5, the O–H stretch at 3425 cm−1 attributed to O–H stretch
of both chitosan and Captisol® remained, while the O–H stretch at 3408 cm−1 of free quercetin
disappeared. The disappearances of both aromatic bending and stretching (1610 cm−1, 1662 cm−1)
and the peaks between 1200 and 1300 cm−1, especially the (C–O–C) peak at 1262 cm−1, together with
the appearance of new glycosidic linkage peak at 1040 cm−1 (shifted from 1042.87 cm−1 of Captisol®)
indicated that quercetin might be entrapped inside the cavity of Captisol® rather than present on
the surface of nanoparticles. A new peak appeared centered at 794.5 cm−1 (attributed to a peak at
795.92 cm−1 of free quercetin) in loaded 4/2/0.5 NPs when compared with unloaded formulation
indicated that quercetin was efficiently associated in the NPs. The disappearance of typical peaks of
quercetin after nanoencapsulation has been reported elsewhere [55,76]. FTIR results have confirmed
the conjugation between quercetin and the NPs matrix.
2.7. Bioassay against E. coli Top 10 of Selected NPs
We have investigated the influences of free quercetin, chitosan, Captisol®, unloaded and
quercetin-loaded nanoparticles at different concentrations to the responses of AHL-regulated biosensor
strain, E. coli Top 10, regarding the evolution of the fluorescence intensity and the bacterial growth
(proportional to OD600). The ratio between fluorescence intensity and OD600 was also calculated and
be defined as relative light unit (RLU). To establishing quantitative comparisons, we have selected
measurement of the last RLU and OD600 (i.e., endpoint measurement after 7 h when the growth rate
is assumed to enter the stationary phase). The QS in the positive control was set as 100%, and the
relative QS of a given treatment is defined as the ratio of its RLU at 7 h with respect to that of the
control. Therefore, theoretically, if the relative QS values are equal to one, it means that the evaluated
compounds do not have any anti-QS effect. In turn, relative QS values lower than one, are diagnostic
of QS inhibition as the OD600 does not decrease. The recorded results are shown in Figure 9. There was
no inhibition effect to bacterial growth at different concentrations of Captisol® (Figure 9a,d) namely,
0.1875, 0.375 and 0.75 mg/mL, which are equivalent to the amount of Captisol® in 4/1/-, 4/2/-,
4/4/-NP formulations, respectively, thus suggesting that Captisol® is non-toxic to bacteria.
However, GFP has reduced significantly in a dose-dependent manner in a range of Captisol®
from 0.1875 to 0.75 mg/mL (Figure 9b,e). Altogether, increasing amounts of free form Captisol®
decreased proportionally relative QS activity from 8.43% to 20.86% (Figure 9h,j). Since the final
concentrations of quercetin of loaded-NPs in the bioassays ranging from 0.0028 mg/mL (lowest in
CS70/20 4/0/1) to 0.0373 mg/mL (highest in CS70/20 4/4/0 NPs), quercetin existing in free form at
three different concentrations namely 0.0125, 0.025 and 0.0375 mg/mL was also tested. CS70/5 and
CS70/20 at the same final concentration in the bioassay (0.75 mg/mL) were also tested. Interestingly,
quercetin existing in free form exerted inhibition effect to bacterial growth as evidenced in Figure 9a,d,
but the reduction of GFP expression is negligible and the differences between treatments are not very
clear. Thus, the free form quercetin exhibited slightly anti-bacterial effect rather than anti-QS effect
(Figure 9h,j). In CS70/5 NPs, chitosan in free form and unloaded NPs showed negligible inhibition on
bacterial growth around 20% (Figure 9a,g). When compared with unloaded NPs, quercetin-loaded
ones revealed a minor decrease on bacterial growth that might attributed to the final amount of
quercetin-loaded in these formulations, ranging from 0.0046 mg/mL in 4/0/0.75 to 0.0178 mg/mL
in 4/2/0.25 (Table S3). Of note, when GFP intensities of loaded-NPs are the lowest (Figure 9b), the
bacterial growth seems to be affected very little by CS70/5 NPs, thus displaying an anti-QS effect.
In fact, when applied in free form, the highest anti-QS effect observed for Captisol® and CS70/5 were
20.86% and 27.0%, respectively (Figure 9h).
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The anti-QS effect of CS70/5 NPs both quercetin-loaded and unloaded increased significantly
when compared with the single components. Interestingly, unloaded 4/2/0.25 containing a double
amount of Captisol® exhibited equivalent anti-QS effect when compared with unloaded 4/1/0.5.
Higher surface charge of unloaded 4/1/0.5 than unloaded 4/2/0.25 nanoparticles (cf. ζ ~+38 vs.
+36.3 mV, respectively) could be an explanation for this phenomenon since electrostatic interaction
between oppositely surface charged of NPs and bacteria favor anti-QS efficiency. It should be noted
that in each formulation, loaded NPs showed stronger anti-QS effect than the unloaded ones, thus
suggesting that quercetin might act synergistically with chitosan and Captisol® in increasing the
anti-QS effect of these NPs system. As we expected, the highest anti-QS effect, up to 62%, was observed
in loaded 4/2/0.25 formulation comprising the greatest amount of Captisol®, thus the concomitant
greatest amount of associated quercetin.
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intensity and relative light unit (FL/OD) of CS70/5 NPs (a–c); of CS70/20 NPs (d–f), respectively. Effect
of different formulations on relative bacterial growth (OD600) and relative QS activity of CS70/5 NPs
(g,h); of CS70/20 NPs (i,j), respectively. (L: loaded NPs, U: unloaded NPs, QUE: quercetin; values
represent mean ± SD, n = 3 with eight technical replicates, statistical significance after ANOVA
multiple comparison analysis with respect to the positive control: * p < 0.05, ** p < 0.01, *** p < 0.001
and **** p < 0.0001).
With CS70/20 NPs, free form of CS70/20 exhibited significantly inhibitory effect to bacterial growth
when 88.67% OD600 reduction was observed in this treatment (Figure 9i). The lower OD600 reduction
observed in unloaded NPs (from 30.1% in unloaded 4/0/1 to 71.33% in unloaded 4/2/0.5) revealed
that upon nanoencapsulation, the toxicity of CS70/20 was significantly reduced (Figure 9d,i). The same
trends were observed when in all formulations loaded NPs showed stronger inhibition effect to
bacterial growth (from 39.48% in loaded 4/0/1 t 88.32% in loaded 4/4/0 formulations) than the
unload d ones (Figure 9d,i). Since almost both unloaded and load d or ulations of CS70/20 NPs,
caused str ng r duction in OD600 (up to 88.32% in loaded 4/4/0 NPs), the e NPs exhibited antibacterial
effect rather than anti-QS effect. The reduction in GFP intensity might stem from the death bacteria that
cannot generate GFP, rather than the inhibition to survival bacteria expressing GFP. The antibacterial
effect in these NPs could be divided into two main groups. The first group which caused slight [+]/[−]
antibacterial effect including unloaded NPs (except for 4/2/0.5 and 4/4/0 formulations), loaded
4/0/1 and loaded 4/3/0. The second group which caused strongly antibacterial effect including
both unloaded and loaded of 4/2/0.5 and 4/4/0 formulations, free CS70/20 (0.75 mg/mL). In general,
formulations containing Captisol® inhibited bacterial growth stro ger whe compared with the control
(formulation 4/0/1 both unloaded and loaded NPs). I unloaded NPs, xcept fo 4/2/0.5 formulation,
the antibacterial effect increased proportionally with the amount of Captisol® (4/3/0 vs. 4/4/0 NPs)
highlighting the crucial role of Captisol®’s cavity in inhibiting bacterial growth and florescence as
well. The stronger effect observed in unloaded 4/2/0.5 when compared with unloaded 4/3/0 and
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unloaded 4/4/0 could be explained by the higher positive surface charged of this NPs formulation
(ζ~+40 mV in 4/2/0.5 vs. ~+32 mV in 4/3/0 and 4/4/0 (Table 2). With the loaded NPs, the higher
amount of quercetin loaded in the NPs matrix, the higher antibacterial activities were observed with
4/3/0 and 4/4/0 formulations. The higher activity of loaded 4/2/0.5 NPs than loaded 4/3/0 NPs
suggesting the synergistic effect between highly positive surface charged of 4/2/0.5 NPs with the
natural Captisol®’s cavity and the antibacterial effect of quercetin as well. It should be noted that free
quercetin and 4/0/1 NPs caused slightly antibacterial effect on bacteria. However, both unloaded
and loaded 4/0/1 NPs could reduce the GPF expression more efficiently when compared with
free quercetin of different concentrations. Quercetin-loaded NPs showed less toxicity to bacterial
than free chitosan, but stronger reduction of GFP were observed with loaded 4/2/0.5 and loaded
4/4/0 NPs suggesting that encapsulation process could reduce the toxicity of NP’s component as well
as enhance GFP inhibitory activities of these NPs. The lowest florescence intensity observed in loaded
4/4/0 formulation suggests that at this concentration (drug releases up to ~40% from the nanoparticle
matrix after 6 h, was equivalent to 0.0298 mg/mL) might be too high and caused the toxic for this
biosensor bacteria.
3. Discussion
CS/SBEβCD nanoparticles were prepared by ionic gelation either in the presence or absence of
TPP. Nanosystems were formed by the combination of the electrostatic interaction between CS and
SBEβCD, which are oppositely charged, and the ability of CS to experience a liquid–gel conversion
due to its ionic interaction with TPP. The initial experiments were aimed at screening the best NPs
formulations using a derivative of β-CD with degree of substitution of 6.4 (SBEβCD) and two kinds
of chitosan namely CS70/5 and CS70/20. As can be seen from the results (Tables 1–4; Figures 1 and 2),
the incorporation capacity of CS could be determined by their degree of acetylation (DA), which are
corresponding to their positive charge. CS70/20 with DA of 21% has shown the higher ability to
incorporate with negatively charged of SBEβCD or mixture of SBEβCD/TPP when compared with
CS70/5 with DA of 32.4%. The best mass ratio (CS/SBEβCD/TPP) formulations of CS70/5 were 4/1/0.5
and 4/2/0.25 whereas those comprising CS70/20 were 4/1/0.75 and 4/2/0.5. Indeed, the [+]/[−]
charge ratio plays an important role in the formation of NPs. In this study, we have shown that
around the stoichiometric point where charge ratio [+]/[−] ≈ 1, NPs could not form and aggregation
occurred immediately. This important result allowed shortening the screening processes for the
best formulations. Charge ratio can also influence the physicochemical properties of the NPs in
terms of size, PDI, zeta potential and production yield. The resulting NPs were in the size range of
250–400 nm with CS70/5 and 330–600 nm with CS70/20, low polydispersity index (<0.25) and always
exhibit high zeta potential (ranging from ζ +31 to +40 mV), thus suggesting that CS is mainly located
on the surface of the particles. It could be noted that production yield of formulations containing
TPP increased significantly. Quercetin, a poorly soluble flavonoid, was chosen for testing the ability
to load hydrophobic drug of the best NPs formulations in previous part. Quercetin-loaded NPs
were characterized in terms of size, PDI, zeta potential and production yield. The results show
that the addition of quercetin did not alter significantly the physicochemical properties of the NPs,
suggesting that quercetin was fully entrapped in the cavity of cyclodextrin. The noncovalent inclusion
complexes formed by Captisol®’s cavity and guest molecules both in solution and the solid state
can lead to alter the physical, chemical and biological properties of guest molecules. The inclusion
complexes in which guest molecule was surrounded by hydrophobic environment of Captisol®’s
cavity is ideal for delivering low solubility drug. Solid inclusion complexes between quercetin and
Captisol® have also been studies before in order to enhance the solubility, dissolution rate, as well as
improve significantly anti-cancer activity at lower quercetin concentration [77]. Quercetin was released
sustainable but higher antioxidant activity and photostability was obtained upon inclusion complexed
with β cyclodextrin [78]. The toxicity of quercetin has also been demonstrated to be reduced upon
complexing with hydroxypropyl β-cyclodextrin elsewhere [79]. Results from Tables 3 and 4 indicate
Molecules 2017, 22, 1975 14 of 23
that Captisol® could facilitate the association of complexed drug into the CS NPs. The association
efficiency in all formulations containing Captisol® was higher than 85% and the loading efficiency
increased linearly with Captisol® amount. When compared with the controls (4/0/0.75 in CS70/5 NPs
and 4/0/1 in CS70/20 NPs), the LE of the best formulation increased up to 2.98 and 8.1 times,
respectively. Interestingly, the LE of the controls (without Captisol®) were negligible and when
the amount of TPP decreased, the AE and LE increase suggesting that TPP might compete with
quercetin in association with CS in these formulations.
Elemental analysis was performed to identify the compositions of selected NP formulations.
The values obtained by this technique are close to the theoretical mass ratios at which the materials
were incorporated. As expected, Captisol® was effectively incorporated into the NPs and representing
up to 52.7% of the total mass in CS70/20 4/3/0 NPs. The preparation of nanoparticles containing more
than 50% mass of SBEβCD is very crucial since SBEβCD is low toxicity and possess special features in
terms of enhancing permeability and protecting drug molecules [80]. The strong interaction between
the SBEβCD and CS is afforded by the presence of negatively charged sulfate groups in the SBEβCD
that ionically interacts with the positively charged CS molecules.
FTIR results indicated that quercetin was effectively entrapped inside the cavity of Captisol®.
This result is very important since quercetin will be released gradually from the nanosytems that
was driven by the exchange between quercetin and autoinducer (3OC6HSL) to occupy the cavity of
Captisol®. The gradualy release has allowed bacteria to have enough time to adapt to the drug and
therefore, help to reduce the toxicity of the nanosystems as well as prolong their anti-QS effect.
Bioassays against E. coli Top10 biosensor have been carried out to evaluate the bioactivities of
NPs derived from two kinds of chitosan with different DA. CS70/5 NPs exhibited highly anti-QS effect
while CS70/20 NPs showed strongly antibacterial effect. This suggests that CS’s DA is a crucial factor
that determine the pathway in which NPs might interfere with bacteria. In fact, both anti-QS and
anti-bacterial activities increased significantly upon nanoencapsulation, thus highlighting the benefit
of unique physicochemical properties and high surface area to volume ratio of NPs that facilitate
their attachment to bacteria’s membrane and enhance the bioactivities effect of the systems as well
as minoring their toxicity. As evidenced in Figure 9, the best anti-QS and anti-bacterial effects were
attained in loaded NPs, suggesting that the synergistic effect of chitosan, Captisol® and quercetin
will optimize the bioactivities of nanosystems. Formulations containing Captisol® (both loaded and
unloaded) showed higher either anti QS or antibacterial effects than the control without Captisol®
(4/0/0.75 and 4/0/1, respectively). This suggests that the exchange between the release of quercetin
outside Captisol®’s cavity and the simultaneously uptake of 3OC6HSL inside this cavity could be
the reason of enhancing bioactivities of these NPs. The uptake of autoinducer inside the cavity
making autoinducer cannot reach adequate threshold to activate the fully QS in E. coli Top10 biosensor.
Our result is in accordance with previous works [73,74,81] that suggested autoinducers, especially
AHLs possessing an acyl chain from C4 to C8 (in our case is 3-oxo-C6-HSL), could be trapped inside
the cavity of Captisol®, thus leading to the reduction in QS activity. Quercetin at concentration of 16
µg/mL has been reported sofar as an effective inhibitor of QS, biofilm formation and QS-regulated
virulence factors in P. aeruginosa PAO1 [82]. The two main QS systems in P. aeruginosa PAO1 are lasI/R
and rhlI/R in which lasI and rhlI are involved in autoinducer synthesis, while lasR and rhlR served
as receptors. E. coli Top 10, biosensor used in our studies, possesses a cassette luxR transformed
from Vibrio fischeri that can only respond to 3OC6HSL but cannot produce autoinducer due to lack of
luxI cassette. Since QS circuits in P. aeruginosa PAO1 and E. coli Top 10 respond to different type of
autoinducers and quercetin exerted anti-QS effect on both systems, we can excluded that quercetin
compete for the binding site of the involved receptors with the cognate autoinducers and different
mechanisms have been hypothesized. One possibility could be that quercetin inhibited autoinducer
synthase enzymes that could be eliminated from our studies, as E. coli Top 10 does not synthesize
autoinducer. Also, quercetin can bind to different domains of LuxR receptor (except for binding site)
that would affect the binding affinity of luxR to luxI-DNA. An alternative explanation is that quercetin
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might be accumulated rapidly at the lipidic membrane of bacteria leading to block the diffusion of
AHL to the cytosol [83]. The last interpretation seems to be the most plausible one, as it can answer
why in free form quercetin exert highly toxic to bacterial growth in a dose dependent manner while
CS70/5-loaded NPs do not. In one hand, quercetin was released in a sustained and controlled manner
from the NPs, permitting bacteria to have enough time to adapt to as well as metabolise this drug. On
other hand, the aggregation effect due to the highly positive charged of these NPs could enhance the
anti-QS of the system since they can deliver their payloads locally at the bacterial cell wall, maintain
the lower dose during the timespan of the experiment and hence prolong the anti-QS effect of the
nanosystems. In addition, our previous study has shown that blank nanocapsules could 100% bind to
E. coli Top 10 at their low concentration below the optimal “stoichiometric” nanocapsule/bacterium
binding point [84]. However, the precise mechanisms underlying these effects remain to be fully
elucidated, and the results need to be confirmed in an in vivo experiment. As a natural QS inhibitor,
quercetin has several advantages. Firstly, quercetin is low in cost and abundant in nature. Secondly,
as reported by available literatures, quercetin would not have any adverse health effect on human
following the oral administration at doses up to 1000 mg per day for up to 12 weeks [85]. Thirdly,
the anti-QS effect observed for quercetin is at very low concentrations, compared with most of plant
extracts and substances before [86,87]. To this end, nanoencapsulation could help to enhance both
anti-QS and anti-bacterial effect of the nanosystems. Chitosan’s DA plays an important aspect in
determining their pathways to interfere with bacteria.
4. Materials and Methods
4.1. Materials
Chitosan samples were of high purity research grade from Heppe Medical Chitosan GmbH
(Halle/Saale, Germany), namely sample Code HMC 70/5 (Batch No. 212-170614-01; degree of
acetylation 32.4% which corresponds to a degree of deacetylation of 67.6%, as determined by 1H-NMR;
molar mass 17.6 Kg·mol−1 as determined by intrinsic viscosity in 0.3 M acetic acid/0.2 M sodium
acetate at 25 ◦C) and sample Code 70/20 (Batch No. 212-100715-03; degree of acetylation of 21% which
corresponds to a degree of deacetylation of 79% and molar mass 78.6 Kg·mol−1, determined by the
same methods as the HMC 70/5 sample). Both chitosan samples used in this study were originated
from crab shell waste by thermoalkaline deacetylation. Sulphobutyl ether-β-cyclodextrin sodium salt
(SBEβCD, Mw = 2163, substitution degree ≈ 6.4) was a kind gift from CyDex, Inc. (Lenexa, KS, USA).
Pentasodium tripolyphosphate (TPP), Quercetin (Mw = 302.24, Log P: 2.16) and 3OC6HSL were
analytical grade and were all purchased from Sigma-Aldrich GmbH (Steinheim, Germany). Ultrapure
Milli-Q water was used throughout.
4.2. Methods
4.2.1. Phase-Solubility Studies
To get insight the kinetics and dynamics of quercetin’s solubility, phase-solubility studies were
performed by adding an excess of the drug to 5 mL solution containing increasing amounts of
SBEβCD (from 0 to 40 mM) in sealed glass containers stirred at 37 ◦C until equilibrium (after 3 days).
The suspension was then filtered (pore size 0.45 µm), and quercetin concentration was identified
spectrophotometrically (λ = 374 nm) (Jasco V-630 spectrophotometer, Labor und Datentechnik,
64319 Pfungstadt, Germany). In keeping with Higuchi and Connors [88], the apparent 1:1 stability
constants were calculated from the straight-line portion of the phase solubility diagrams.
4.2.2. Preparation of Nanoparticles (NPs)
NPs composed of CS and SBEβCD or mixtures of SBEβCD/TPP were obtained via the ionotropic
gelation technique [65] with slight modifications. The methods are detailed briefly below:
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(a) NPs without CD: were spontaneously formed at room temperature upon addition of 1 mL of
TPP aqueous solution (0.15% w/v, polyanionic phase) to 3 mL of the CS solution (0.20% w/v, pH 4.95,
polycationic phase) under stirring (850 rpm, 10 min). The solution was then kept stable for at least
50 min to allow the complete stabilization of the system.
(b) NPs containing CD: The volumes of the two phases were always the same as well as for
NPs without CD. CS/SBEβCD/TPP NPs were prepared by mixing the CS solution (0.2% w/v) with a
polyanionic phase containing SBEβCD (0.15–0.9% w/v) or both SBEβCD and TPP (0.075–0.3% w/v).
(c) Preparation of quercetin-loaded nanoparticles: For the association of quercetin into the NPs system,
an excess of quercetin was incubated under magnetic stirring (500 rpm, 24 h) with either water solution
containing different amounts of SBEβCD (from 3.0 to 6.0 mg/mL) or CS solution (0.2% w/v, pH 4.95).
After incubation, the drug suspensions were filtered through 0.45 µm membrane and the resulting
solutions was identified spectrophotometrically for quercetin content. This inclusion-complexed solution
was then used for NP formation by the ionotropic gelation technique as described above.
The resulting NPs were isolated by ultracentrifugation on a glycerol bed (10,000× g, 40 min,
15 ◦C; Mikro 220 R, Hettich GmbH & Co. KG, Tuttlingen, Germany). Supernatants were collected
for determination of the amount of unbound quercetin. NPs were then re-suspended in 100 µL NaCl
85 mM. Glycerol was used to enhance the re-suspend ability of centrifuged nanoparticles.
The production yield of the nanoparticles was obtained by centrifuging fixed volumes of the
freshly prepared nanoparticles suspensions (16,000× g, 40 min, room temperature) without glycerol
bed. The supernatants were then discarded, and the pellets were lyophilized at −50 ◦C until constant
weight (after 2 days). The production yield was calculated by comparing the actual weight with the
theoretical weight of the total components of nanoparticles.
4.2.3. Physicochemical Characterization of Nanoparticles
The Z-average particle size (hydrodynamic diameter) and size distribution of the NPs were
determined by dynamic light scattering with non-invasive back scattering (DLS-NIBS) at 25 ◦C detected
at an angle of 173◦ fitted with a red laser light output (λ = 632.8 nm) using a Malvern Zetasizer Nano
ZS instrument (ZEN3600, Malvern Instruments Ltd., Malvern, UK). The ζ-potential was measured by
phase analysis light scattering and mixed laser Doppler velocimetry (M3-PALS) at 25 ◦C. The samples
were diluted 1:20 in 1 mM KCl before measurement.
4.2.4. Elemental Analysis of the NPs
Unloaded nanoparticles were prepared as described above, without using glycerol bed during
centrifugation, and finally lyophilized (Telstar Cryodos, Terrassa, Spain). Elemental analysis of the
starting materials (i.e., pure CS and pure SBEβCD) and the lyophilized nanoparticles was analyzed by
Elemental Analyzer Telstar (Telstar Cryodos freeze-drier, Telstar Industrial SL, Terrassa, Spain). For all
samples, the elemental composition of C, H and N was determined. For the SBEβCD (pure component)
and CS/SBEβCD NPs, the corresponding composition of S was also determined. The CS content of the
NPs sample was analyzed by comparing the N content between the samples and pure CS. For SBEβCD
content determination, the C content of the samples arising from CS was calculated and subtracted
from the total C amount. The remaining amount of C was used to calculate the amount of SBEβCD by
comparing that C amount with that of pure SBEβCD. In the case of the CS/SBEβCD/TPP NPs, the S
content was also used for SBEβCD quantification. Hence, the reported data represent an average of
the two results. The remaining fraction of the NPs composition was attributed to TPP.
4.2.5. Loading and Association Efficiency of Nanoparticles
The association efficiencies of the nanoparticle formulations were determined after isolation
of nanoparticles by centrifugation as described in Section 4.2.2. Supernatants were collected for
determination of the amount of unbound quercetin using spectrophotometry method. The loading
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efficiency (LE%) and the association efficiency (AE%) of quercetin were calculated according with
Equations (1) and (2), respectively, namely:
Loading efficiency (%) =
Totaldrug−mass − Freedrug−mass
Nanoparticlesmass
× 100 (1)
Association efficiency (%) =
[
TotalDrug
]− [FreeDrug][
TotalDrug
] × 100 (2)
4.2.6. Stability Study in M9 Medium
Stability study has been conducted following the protocol used in our previous studies [89].
Briefly, selected nanoparticle formulations were prepared and centrifuged in the presence of glycerol
bed. Unloaded-nanoparticles and quercetin-loaded nanoparticles were tested for their stability in M9
medium in terms of the change in size and the polydispersity index (PDI) of nanoparticles and possible
precipitations. Nanoparticles were incubated in M9 medium at 37 ◦C with agitation of 100 rpm.
The size distribution of the nanoparticles and PDI were measured by photon correlation spectroscopy
at different time points of 0, 30, 60, 120, 240 and 420 min. Each experiment was performed in triplicates.
4.2.7. In Vitro Release Studies
It was done according to method developed by Kaiser et al., with slightly modifications [49].
Briefly, quercetin-loaded NPs were isolated and re-suspended in NaCl 85 mM. The release studies
were performed by incubating 800 µL Quercetin-loaded NPs suspension in 25 mL of M9 medium at
37 ◦C and then, stirred at 100 rpm. At appropriate time points, the samples were withdrawn, replaced
by fresh M9 medium and centrifuged at 16,000× g for 30 min. The drug released from the NPs, present
in the supernatant, was determined by UV/Vis spectrophotometry at 374 nm and was calculated by
interpolation using a calibration curve.
4.2.8. FTIR Spectroscopy Studies
The spectra of Fourier transform infrared spectroscopy (FTIR) was used to analyze molecular
bonding formation between QUE and chitosan nanoparticles. The FTIR spectra of pure QUE and
QUE-loaded chitosan nanoparticles were recorded using Perkin Elmer Nicolet 520 spectrophotometer
(Perkin Elmer, Boston, MA, USA). The lyophilized samples were ground with spectroscopic grade
potassium bromide (KBr) powder and then, pressed into 1 mm pellet for FTIR measurement in the
range of 450–4000 cm−1 with 4 cm−1 resolution, using 16 scans. All samples were analyzed and
recorded in triplicates.
4.2.9. QS Inhibition Studies
(a) E. coli Top 10 Biosensor Strain
The bacterial strain used for all experiments was a fluorescence biosensor constructed from an
E. coli Top 10 (Invitrogen, Life Technologies Co., Paisley, UK), which had been transformed chemically
by Celina Vila of our laboratory to contain the standard biological part BioBrick_T9002 on the plasmid
BBa pSB1A3 (http://partsregistry.org/Part:BBa_T9002), kindly donated by Prof. Anderson’s lab
(UC Berkeley, Berkeley, CA, USA). The sequence BBa T9002, comprised the luxR gene, coding for the
transcriptional factor LuxR, under the control of the pTetR promoter, being expressed in a constitutive
manner. Upon external addition of 3OC6HSL, the dimerization of two monomeric species of LuxR,
each bound to one AHL molecule, drives to activation of gfp expression through binding of the
LuxR-AHL dimerized complex to the lux pR promoter from Vibrio fischeri, and initiates the production
of green fluorescent protein when 3OC6HSL is added. This strain has been used in previous studies in
our laboratory [36,84].
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(b) E. coli Top 10 Biosensor Assay
The bacterial strain was cultivated in Luria-Bertani (LB) medium supplemented with 200 µg/mL
ampicillin for 18 h at 37 ◦C, shaking at 100 rpm and then was stored at−80 ◦C in 30% sterile glycerol for
future use. Before the biosensor assay, the bacteria working solution was prepared by cultivating 40 µL
of bacteria stored in cryo-tube at −80 ◦C into 20 mL M9 medium plus 20 µL of ampicillin (200 µg/mL),
under incubation at 37 ◦C, 100 rpm, until the OD600 reached 0.04~0.07 (~4 h). 3OC6HSL was dissolved
in acetonitrile to a stock concentration of 100 mM and stored at −20 ◦C. Five µL aliquot of the 100 mM
3OC6HSL stock solution was diluted with sterile milli-Q water to a working concentration of 10 nM.
QS inhibition activity was tested in 96-well microplate, in which 10 µL of 10 nM 3OC6HSL, 10 µL of the
treatment nanoparticles formulations and 180 µL aliquots of the bacterial culture of OD600 0.04~0.07
were added. Two kinds of blank were set up. Blank 1 (OD blank) contained 180 µL of M9 medium and
20 µL of milli-Q water. Blank 2 (flourescence blank) contained 180 µL of bacterial culture and 20 µL
of milli-Q water to measure the auto-flourescence of the bacteria itself. Positive control contained
180 µL of bacterial culture and 10 µL of milli-Q water and 10 µL of AHL has also been set up to
compare the anti-QS effect of different formulations. The plates were incubated in a Spectra Max-M2
Microplate Reader (Molecular Devices, Sunnyvale, CA, USA) at 37 ◦C. Fluorescence measurements
were recorded automatically using a repeating procedure (λexcitation = 480 nm and λemission = 510 nm,
40 µs, 10 flashes, gain 100, top fluorescence), growth measurements (OD600) (λ = 600 nm absorbance
filter, 10 flashes) and shaking (5 s, orbital shaking, high speed). The interval between measurements
was 60 min. For each experiment, the fluorescence intensity (FI) and OD600 values were obtained
by subtracting the received values with the fluorescence blank and OD blank above, respectively.
All measurements were taken in triplicates.
5. Conclusions
In this study, we have developed novel nanocarrier formulations consisting of chitosan and
a negatively charged cyclodextrin, Captisol®, via the very mild ionotropic gelation technique.
The charge ratio [+]/[−] determined the final physicochemical characteristics of the resulting NPs.
The nanoparticles exhibited a small size, a positive zeta potential and a great capacity for the
association of quercetin. Quercetin-loaded NPs showed to be stable in bacterial M9 medium for
7 h. The presence of Captisol® in the NPs plays an important role in controlling the release rate of
quercetin. Chitosan-based NPs can be used as an effective vehicle to deliver hydrophobic bioactive
compounds locally to the bacterial surface, as well as to enhance both their anti-QS and anti-bacterial
activities. The exact mechanism in which NPs interact with the E. coli Top 10 biosensor remains to be
elucidated and is currently being addressed in our Laboratory.
Supplementary Materials: The supplementary materials are available online.
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